

Colloton Robert C
 Form 4
 September 28, 2010

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Colloton Robert C

2. Issuer Name and Ticker or Trading Symbol
 MICRUS ENDOVASCULAR CORP [MEND]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
 821 FOX LANE
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 09/27/2010

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 VP Global Sales & Marketing

SAN JOSE, CA 95131
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D) Price			
Common Stock	09/27/2010		D	25 D <u>1</u> 0		D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Colloton Robert C - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 9.19	09/27/2010		D		16,145		<u>(2)</u>	05/26/2019	Common Stock	16,145
Stock Option (Right to Buy)	\$ 11.42	09/27/2010		D		6,042		<u>(2)</u>	05/14/2018	Common Stock	6,042
Stock Option (Right to Buy)	\$ 9.19	09/27/2010		D		8,855		<u>(2)</u>	05/26/2019	Common Stock	8,855
Stock Option (Right to Buy)	\$ 9.25	09/27/2010		D		40,943		<u>(2)</u>	01/06/2016	Common Stock	40,943
Stock Option (Right to Buy)	\$ 21.04	09/27/2010		D		18,077		<u>(2)</u>	05/29/2017	Common Stock	18,077
Stock Option (Right to Buy)	\$ 21.04	09/27/2010		D		6,923		<u>(2)</u>	05/29/2017	Common Stock	6,923
Stock Option (Right to Buy)	\$ 5.625	09/27/2010		D		57,913		<u>(2)</u>	02/23/2015	Common Stock	57,913
Stock Option (Right to Buy)	\$ 5.625	09/27/2010		D		53,197		<u>(2)</u>	02/23/2015	Common Stock	53,197
Stock Option (Right to Buy)	\$ 11.42	09/27/2010		D		13,958		<u>(2)</u>	05/14/2018	Common Stock	13,958

Stock Option (Right to Buy)	\$ 9.25	09/27/2010	D	9,057	(2)	01/06/2016	Common Stock	9,057
--------------------------------------	---------	------------	---	-------	-----	------------	-----------------	-------

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Colloton Robert C 821 FOX LANE SAN JOSE, CA 95131			VP Global Sales & Marketing	

Signatures

/s/ Carolyn M. Bruguera, Attorney-in-Fact for Robert C. Colloton	09/28/2010
---	------------

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., each share of common stock held by the reporting person was converted into the right to receive \$23.40 in cash, without interest.

(2) Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., this stock option was converted into the right to receive an amount in cash per share subject to the stock option equal to the excess of the per share merger consideration of \$23.40 over the per share exercise price of such stock option, without interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.